Oncology -Capecitabine Prior Authorization
Cigna prior authorization policy for capecitabine (Xeloda® and generics) for outpatient prescription benefit coverage, listing FDA-approved indications and other uses with supportive evidence and approval durations/age criteria. Applies to Cigna-administered health benefit plans unless a client's plan document or delegated vendor guidance dictates otherwise.
Biliary Tract Cancer condition of approval was changed from 'hepatobiliary cancer' to 'biliary tract cancer'.
Cervical, Endometrial, Vaginal, and Vulvar Cancers were added to Other Uses With Supportive Evidence in prior revisions.
Coverage Summary & Criteria
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.